What are analysts Suggestions on Ocular Therapeutix, Inc.(NASDAQ:OCUL): Editas Medicine, Inc.(NASDAQ:EDIT)

0
6

Ocular Therapeutix, Inc. (OCUL) will report its next earnings on Aug 09 BMO. The company reported the earnings of $-0.41/Share in the last quarter where the estimated EPS by analysts was $-0.42/share. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 2.4%.

Many analysts are providing their Estimated Earnings analysis for Ocular Therapeutix, Inc. and for the current quarter 4 analysts have projected that the stock could give an Average Earnings estimate of $-0.48/share. These analysts have also projected a Low Estimate of $-0.49/share and a High Estimate of $-0.46/share.

In case of Revenue Estimates, 5 analysts have provided their consensus Average Revenue Estimates for Ocular Therapeutix, Inc. as 740 Million. According to these analysts, the Low Revenue Estimate for Ocular Therapeutix, Inc. is 200 Million and the High Revenue Estimate is 2 Million. The company had Year Ago Sales of 648 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for OCUL to be -13.5%. They are projecting Next Quarter growth of 2.63%. For the next 5 years, Ocular Therapeutix, Inc. is expecting Growth of 46.72% per annum, whereas in the past 5 years the growth was 7.64% per annum.

Some buy side analysts are also providing their Analysis on Ocular Therapeutix, Inc., where 2 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Ocular Therapeutix, Inc. might touch $24 high while the Average Price Target and Low price Target is $9.67 and $3 respectively.

Ocular Therapeutix, Inc. closed its last trading session at $4.8 with the gain of 1.25%. The Market Capitalization of the company stands at 215.49 Million. The Company has 52-week high of $7.31 and 52-week low of $2.35. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 2.1% where SMA50 and SMA200 are 24.34% and 8.84% respectively. The Company Touched its 52-Week High on 10/01/18 and 52-Week Low on 05/21/19.

The Relative Volume of the company is 0.67 and Average Volume (3 months) is 934.14 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -80.4%. The Return on Equity (ROE) value stands at -165.8%. While it’s Return on Investment (ROI) value is -97.4%.

While looking at the Stock’s Performance, Ocular Therapeutix, Inc. currently shows a Weekly Performance of -5.45%, where Monthly Performance is 8.48%, Quarterly performance is 33.15%, 6 Months performance is 22.73% and yearly performance percentage is -21.86%. Year to Date performance value (YTD perf) value is 22.11%. The Stock currently has a Weekly Volatility of 7.50% and Monthly Volatility of 7.90%.

Editas Medicine, Inc. (EDIT) will report its next earnings on Aug 06 AMC. The company reported the earnings of $-0.32/Share in the last quarter where the estimated EPS by analysts was $-0.66/share. The difference between the expected and actual EPS was $0.34/share, which represents an Earnings surprise of 51.5%.

Many analysts are providing their Estimated Earnings analysis for Editas Medicine, Inc. and for the current quarter 0 analysts have projected that the stock could give an Average Earnings estimate of $0/share. These analysts have also projected a Low Estimate of $0/share and a High Estimate of $0/share.

In case of Revenue Estimates, 5 analysts have provided their consensus Average Revenue Estimates for Editas Medicine, Inc. as 18.7 Million. According to these analysts, the Low Revenue Estimate for Editas Medicine, Inc. is 1.5 Million and the High Revenue Estimate is 32 Million. The company had Year Ago Sales of 3.67 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for EDIT to be 28.1%. They are projecting Next Quarter growth of -106.25%. For the next 5 years, Editas Medicine, Inc. is expecting Growth of -13.82% per annum, whereas in the past 5 years the growth was -8.15% per annum.

Some buy side analysts are also providing their Analysis on Editas Medicine, Inc., where 0 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 1 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Editas Medicine, Inc. might touch $55 high while the Average Price Target and Low price Target is $40.5 and $32 respectively.

Editas Medicine, Inc. closed its last trading session at $24.06 with the gain of 2.54%. The Market Capitalization of the company stands at 1.22 Billion. The Company has 52-week high of $36.70 and 52-week low of $17.80. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 3.54% where SMA50 and SMA200 are 7.98% and 0.2% respectively. The Company Touched its 52-Week High on 07/20/18 and 52-Week Low on 12/24/18.

The Relative Volume of the company is 0.69 and Average Volume (3 months) is 721.99 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -27.4%. The Return on Equity (ROE) value stands at -47.6%. While it’s Return on Investment (ROI) value is -42.3%.

While looking at the Stock’s Performance, Editas Medicine, Inc. currently shows a Weekly Performance of -0.44%, where Monthly Performance is 7.31%, Quarterly performance is -4.08%, 6 Months performance is -6.05% and yearly performance percentage is -32.34%. Year to Date performance value (YTD perf) value is 8.44%. The Stock currently has a Weekly Volatility of 3.42% and Monthly Volatility of 3.94%.

SHARE